全球数位治疗市场的成长机会

Growth Opportunities in the Global Digital Therapeutics Market

出版日期: 2023年09月21日 | 出版商:

Frost & Sullivan | 英文 97 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录

预防性医疗保健和市场进入策略刺激新的成长机会

该研究报告提供了全球数位治疗 (DTx) 市场的整体和细分收益预测，并强调了全球 DTx 市场参与企业的关键成长机会。

患有长期慢性病的患者越来越多地寻求安全、循证的数位治疗，以减少药物剂量、引发不利事件并限制医疗保健的利用。部分原因是与这些疾病相关的高昂医疗费用以及对有效且负担得起的解决方案的需求。付款人和医疗保健提供者正在寻求具有成本效益的替代，以提高患者的参与度、依从性和便利性，同时促进基于价值的护理。疾病逆转和预防性医疗保健解决方案的需求也很高。生命科学 (LS) 公司的目标是开发「围绕锭剂」的组合药物，以改善患者的治疗体验。我们也正在寻找对未来药物研发有用的数位生物标记。 LS 与 DTx 公司合作，扩大其产品线并开发新的治疗方法，以满足未满足的医疗需求。此外，LS 还帮助 DTx 公司扩大其全球患者覆盖范围并实现其健康公平目标。 DTx 供应商和医疗设备公司之间的合作也促进了个体化治疗的给药最佳化。

大多数数位医疗技术长期以来无法透过同行评审的报告系统地证明其解决方案的临床有效性。因此，他们无法获得法规的「处方笺级」数位治疗计划的独特特征，从而同时确保改善患者的治疗效果和全面的报销。在严格、高品质、去中心化的临床试验的支持下，更多的DTx公司正在利用强大的临床资料、RWE资料和HEOR来证明产品的安全性和有效性，并推动广泛的商业化，重点可能会放在资料创建上。

此外，生物製药、医疗设备和医疗技术的整合将在向整合患者管理和整个患者旅程的整体支持的转变中发挥关键作用。专注于患者体验的 DTx 公司利用针对不同客户类型量身定制的各种商业模式，医生推荐产品，患者在规定的时间内持续使用该产品，看护者24/7 全天候使用该产品。系统必须监控结果并启用可扩展的解决方案，允许付款人偿还使用成本。

DTx 和 LS 公司之间的合作扩大了患者覆盖范围，并与风险分担协议一起提高了扩充性。 DTx疗法目前被认为是传统药物疗法的有效辅助性治疗，并受到全面法规。 FDA、NHS 和 CE 等国家和州级法规机构根据特定患者群体临床结果改善的证据授予处方资格。

美国是全球成长的关键市场，其次是欧洲，德国在该地区处于领先地位，因为它对 DTx 采用最具吸引力。这是由于高报销率以及付款人、医疗保健提供者以及生命科学和医疗设备业的公司的早期采用。

疾病管理应用预计将占全球 DTx 市场收益的大部分。这些解决方案提高了患者对慢性病管理的参与度，减少了医疗保健利用率，并鼓励症状自我管理。因此，医疗保健提供者越来越多地将这些解决方案纳入其辅助治疗方法的一部分。糖尿病在治疗领域中拥有最高的销售份额，预期年复合成长率较高。这是因为世界上不断增长的糖尿病人口正在增加对糖尿病管理解决方案的需求。此外，製药公司与用于互联护理的数位胰岛素管理解决方案之间的合作也在不断增加。由于全球对心理健康和认知健康解决方案的高需求，以及雇主与 DTx 供应商合作提供提高员工生产力和健康的解决方案，健康和行为管理领域正在不断增长。收益预计将增长。沉浸式疗法正在成为一种针对难以达到的高风险行为健康状况的有效治疗方法，并且可能会增加患者的参与度。

付款人是为 DTx 市场贡献收益的关键商业用户。预计付款人将透过各种基于价值的付款计划偿还市场收益的 60% 至 66%，患者可根据医生或处方者的推荐自动获得这些付款计划的资格或註册。此外，医疗保健提供者的角色将至关重要，因为 DTx 解决方案可增强整体处方者体验并提高当前的护理标准。

人均医疗保健支出分析
DTx 的核准和跨治疗领域的多元化
主要市场趋势
利用 DCT 模型开拓商业性潜力
美国和欧洲的法规预测
DTx-法规展望：亚太地区
法规预测：中东、非洲和加勒比海地区
全球赎回和市场进入趋势
资金筹措形势
商业模式描述
Top 5 商业模式总结分析
预测假设和限制
收益和预测
按应用分類的收益预测
收益预测分析
地区收益预测
区域收益预测分析 - 北美和欧洲
区域收益预测分析 - 亚太地区
按地区分類的收益预测分析 - 中东和非洲、拉丁美洲、加勒比海地区
按治疗领域分類的收益和预测
收益预测与考察- 治疗领域
按业务分類的销售份额
按业务分類的销售份额分析
价格趋势和预测分析
竞争环境
收益占有率
收益占有率分析
主要竞争对手和提供的产品

成长机会分析疾病管理

成长指标
收益和预测
预测分析 - 疾病管理
使用案例- 疾病管理中的采用

成长机会分析行为与健康管理

成长指标
收益和预测
预测分析 - 健康与行为管理
使用案例- 健康与行为管理的采用

成长机会宇宙

成长机会1：以DTx治疗癌症相关疼痛，提供疾病预测，提升生活品质
成长机会2：慢性病用药依从性与个体化辅导解决方案
成长机会 3：预测和预防医学的数位生物标记
成长机会 4：个体化照护的身临其境型疗法

下一步

下一步
为什么现在要霜冻？
附件清单
免责声明

简介目录

Product Code: PF19-52

Preventive Care and Market Access Strategies Spur New Growth Opportunities

This study presents Frost & Sullivan's overall market and segment-wise revenue forecasts of the global digital therapeutics (DTx) market and highlights key growth opportunities for global DTx market participants.

Patients with long-term chronic conditions increasingly seek safe, evidence-based digital treatments to reduce their medication dosages, reverse triggers of adverse events, and limit healthcare utilization. This is due to the high cost of care associated with these conditions and the need for effective and affordable solutions. Payers and providers seek cost-effective medication alternatives to improve patient engagement, adherence, and convenience while promoting value-based care. The need for disease-reversal and preventive care solutions is also seeing huge demand. Life sciences (LS) companies aim to develop 'around the pill' combination products to enhance patients' treatment experiences. They are also searching for digital biomarkers to assist in drug discovery in the future. LS is partnering with DTx companies to expand their pipelines and develop new treatments for unmet medical needs. In addition, LS is helping DTx companies grow their patient reach globally and achieve their health equity objectives. Collaborations between DTx vendors and medical device companies are also facilitating dosage optimization for personalized therapeutics.

Most digital health technologies have long suffered from being unable to systematically prove their solutions' clinical efficacy via peer-reviewed reports. Thus, they have never secured the unique distinction of being a regulated and "prescription-grade" digital treatment plan that guarantees improved patient outcomes and comprehensive reimbursement at the same time. With the support of rigorous and high-quality decentralized clinical trials, more DTx companies will focus on generating strong clinical, RWE, and HEOR data to prove the safety and effectiveness of their products and drive widespread commercialization.

Additionally, the convergence of biopharma, medical devices, and health technology will play a significant role in shifting toward integrated patient management and holistically supporting the entire patient journey. DTx companies focused on the patient experience must utilize a variety of business models tailored to different customer types, allowing for scalable solutions that enable physicians to recommend their products, patients to use them consistently for a defined period, caregivers to monitor outcomes round the clock, and payers to reimburse the cost of usage.

Collaboration between DTx and LS companies will increase, enabling broader patient reach and increasing scalability alongside risk-sharing agreements. DTx solutions are now considered valid alternatives or adjuncts to traditional pharmacotherapy and are subject to comprehensive regulation. They have been granted prescription status by national or state-level regulatory agencies, such as the FDA, NHS, and CE, based on evidence of improved clinical outcomes for specific patient groups.

The United States is a significant market for growth on a global scale, followed by Europe, where Germany leads the way owing to the highest DTx adoption attractiveness in this region. It is due to higher reimbursement rates and early adoption by payers, providers, and companies in the life sciences and medical device industries.

The disease management application is expected to make up a significant portion of the DTx market revenue worldwide. These solutions enable better patient engagement in chronic care management, lowering healthcare utilization and encouraging self-management of symptoms. This, in turn, incentivizes providers to incorporate these solutions as part of adjunct treatment approaches. Diabetes is expected to have the highest share in revenue within therapy areas and a high CAGR growth rate. This is due to the increasing demand for diabetes management solutions caused by the rising diabetic population worldwide. Additionally, there has been an increase in partnerships between pharma and digital insulin management solutions for connected care. The wellness and behavior management sector will experience revenue growth due to the high demand for mental and cognitive health solutions globally, as well as employers partnering with DTx vendors to provide solutions that enhance employee productivity and wellness. Immersive therapeutics will emerge as an effective treatment approach targeting hard-to-reach and high-risk behavioral health conditions, enhancing patient engagement.

Payers are the primary business users contributing to DTx market revenue. They are expected to reimburse 60% to 66% of the market revenue through different value-based payment plans that patients will be automatically eligible for or subscribed to based on referrals from physicians or formulary decision-makers. Additionally, the role of the providers will become significant as DTx solutions enhance the entire prescriber experience and elevate the current standard of care.

Strategic Imperatives

Why is it Increasingly Difficult to Grow?
The Strategic Imperative 8™
The Impact of the Top 3 Strategic Imperatives on the Digital Therapeutics Industry
Growth Opportunities Fuel the Growth Pipeline Engine™

Growth Opportunity Analysis

Scope of Analysis
Introduction to DTx Solutions
The Ten Core Principles All DTx Must Follow
DTx Product Categorization
DTx Mechanisms and Delivery Routes
Application, Therapy Area, and Business Segmentation
Market Segmentation By Application
Market Segmentation By Therapy Area
Segmentation by Geography
Key Competitors
Growth Metrics
Growth Drivers
Growth Restraints

Growth Environment

Per Capital Healthcare Spending Analysis
DTx Approval and Diversification Across Therapy Areas
Key Market Trends
Unlocking Commercial Viability Through DCT Model
Regulatory Outlook-United States and Europe
DTx-Regulatory Outlook: APAC
Regulatory Outlook, MENASA, LATAM, and the Caribbean
Global Reimbursement and Market Access Trends
Funding Landscape
Business Model Description
Summary Analysis of the Top 5 Business Models
Forecast Assumptions and Limitations
Revenue Forecast
Revenue Forecast by Application
Revenue Forecast Analysis
Revenue Forecast by Region
Revenue Forecast Analysis by Region-North America and Europe
Revenue Forecast Analysis by Region-APAC
Revenue Forecast Analysis by Region-MENASA, LATAM, and the Caribbean
Revenue Forecast by Therapy Area
Revenue Forecast Discussion-Therapy areas
Revenue Share by Business
Revenue Share Analysis by Business
Pricing Trends and Forecast Analysis
Competitive Environment
Revenue Share
Revenue Share Analysis
Key Competitors and Product Offerings

Growth Opportunity Analysis: Disease Management

Growth Metrics
Revenue Forecast
Forecast Analysis-Disease management
Use Cases-Adoption in Disease Management

Growth Opportunity Analysis: Behavior and Wellness Management

Growth Metrics
Revenue Forecast
Forecast Analysis-Wellness and Behavior Management
Use Cases-Adoption in Wellness and Behavioral Management

Growth Opportunity Universe

Growth Opportunity 1: DTx to Treat Cancer-related Distress, Provide Incidence Prediction, and Elevate QoL
Growth Opportunity 2: Drug Adherence and Personalized Coaching Solutions for Chronic Diseases
Growth Opportunity 3: Digital Biomarkers for Predictive and Preventive Care
Growth Opportunity 4: Immersive Therapeutics for Personalized Care